Avicanna Inc.AVCN.TO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · avicanna.com

Avicanna Inc. is a commercial-stage international biopharmaceutical company focused on the development, manufacturing, and commercialization of cannabinoid-based products and formulations for global medical and pharmaceutical markets. The company operates four commercial pillars: Medical Cannabis Products (RHO Phyto), a Medical Cannabis Care Platform (MyMedi.ca), a pharmaceutical pipeline, and active pharmaceutical ingredients under the Aureus Santa Marta brand.

Key ratios

FCF / Sales

-7.0%TTM

2025 -5.6%2024 -11.6%2023 -8.6%

Net margin

-10.8%TTM

2025 -10.8%2024 -14.2%2023 -52.1%

ROA

-8.4%TTM

2025 -8.4%2024 -13.9%2023 -26.5%

ROE

-26.1%TTM

2025 -26.1%2024 -40.9%2023 -153.0%

Recent news

Avicanna to Present at a Life Sciences Investor Forum on September 17, 2026 2026-09-15 · GlobeNewswire Avicanna Launches MyMedi.ca Integrated Healthcare Program in Canada 2026-09-09 · GlobeNewswire Avicanna Announces Closing of Strategic Non-Brokered Private Placement 2026-08-19 · GlobeNewswire Avicanna Reports Q2 2026 Financial Results 2026-08-14 · GlobeNewswire Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio 2026-07-16 · GlobeNewswire Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare 2026-06-15 · GlobeNewswire Avicanna Announces Closing of Non-Brokered Private Placement 2026-06-12 · GlobeNewswire Avicanna Reports Q1 2026 Financial Statements 2026-05-14 · Globe and Mail Avicanna Announces Results of Annual General and Special Meeting 2026-05-08 · GlobeNewswire Avicanna Reports Full Year 2025 Audited Financial Statements 2026-04-01 · GlobeNewswire

Track AVCN.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer